GlassScriptPhysician profile
Oluwatosin Smith
NPI 1134150675
$1,537,357.10
in general payments reported to CMS, 2019-2025
26 companies · $293K in 2025
The $293K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197K · 2020: $173K · 2021: $210K · 2022: $166K · 2023: $216K · 2024: $282K · 2025: $293K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $589K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $61K · Travel and Lodging: $22K · Food and Beverage: $12K · Grant: $10K · Honoraria: $6,100 · Entertainment: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $589,069.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,731.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $60,625.00 |
| Travel and Lodging | $21,628.14 |
| Food and Beverage | $11,948.59 |
| Grant | $10,000.00 |
| Honoraria | $6,100.00 |
| Entertainment | $242.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $829,684.94 | 2019-2025 | Idose, Istent Trabecular Micro-Bypass Stent System, Second Generation Travoprost Intracameral Implant (Trex) |
| Allergan, INC. | $224,509.33 | 2019-2022 | |
| Abbvie INC. | $153,447.95 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Lumigan |
| Bausch & Lomb Americas INC. | $87,113.28 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $85,349.58 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Aerie Pharmaceuticals, INC. | $62,288.32 | 2019-2021 | |
| Alcon Research LLC | $44,390.00 | 2022-2025 | Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24,021.82 | 2019-2021 | |
| New World Medical,INC. | $16,254.21 | 2019-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Nova Eye, INC. | $3,541.67 | 2023-2025 | |
| Thea Pharma INC. | $2,981.96 | 2023-2025 | Iyuzeh |
| Oculus Surgical INC. | $1,700.00 | 2025 | |
| Iridex Corporation | $739.09 | 2019-2023 | |
| Sight Sciences, INC. | $429.00 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $174.61 | 2019-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $149.56 | 2019-2025 | |
| Biotissue Holdings INC. | $129.84 | 2019-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $111.83 | 2019-2022 | |
| Rxsight INC | $99.23 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Harrow Eye, LLC | $94.51 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $38.22 | 2019-2021 | |
| Dompe US, INC. | $33.70 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $31.22 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $22.49 | 2024 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $20.74 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oluwatosin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.